{
    "id": 9820,
    "fullName": "CXCR4 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type CXCR4 indicates that no mutation has been detected within the CXCR4 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7852,
        "geneSymbol": "CXCR4",
        "terms": [
            "CXCR4",
            "CD184",
            "D2S201E",
            "FB22",
            "HM89",
            "HSY3RR",
            "LAP-3",
            "LAP3",
            "LCR1",
            "LESTR",
            "NPY3R",
            "NPYR",
            "NPYRL",
            "NPYY3R",
            "WHIM",
            "WHIMS"
        ]
    },
    "variant": "wild-type",
    "createDate": "07/29/2015",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2632,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing wild-type CXCR4 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9814,
                "profileName": "CXCR4 wild-type MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13547,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 9814,
                "profileName": "CXCR4 wild-type MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13549,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstr\u00f6m's macroglobulinemia, with the best response seen in patients harboring the MYD88 L265P and wild-type CXCR4 genotype (100%, 91.2%, 35 patients), followed by MYD88 L265P and mutant CXCR4 (85.7%, 61.9%, 21 patients), then wild-type MYD88 and CXCR4 (71.4%, 28.6%, 7 patients) (PMID: 25853747; NCT01614821).",
            "molecularProfile": {
                "id": 29153,
                "profileName": "CXCR4 wild-type MYD88 wild-type"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60901,
                "name": "Waldenstroem's macroglobulinemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2810,
                    "pubMedId": 25853747,
                    "title": "Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25853747"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9813,
            "profileName": "CXCR4 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9814,
            "profileName": "CXCR4 wild-type MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29153,
            "profileName": "CXCR4 wild-type MYD88 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}